Clinical Trials Logo

Clinical Trial Summary

explore the effectiveness and safety of conventional transarterial chemoembolization (cTACE) or transarterial chemoembolization (DEB-TACE) plus hepatic arterial Infusion chemotherapy (HAIC) combined with regorafenib and anti-PD-1 antibody or not for unresected hepatocellular carcinoma (uHCC)

Clinical Trial Description

This is a non-randomized, open, single-arm clinical study. Patients receive cTACE/DEB-TACE+HAIC treatment( 6-8 weeks as a cycle) and regorafenib and anti-PD1 antibody or not until the disease progresses, intolerable toxicity occurs, the patient is lost to follow-up or death, or situations other judged by researchers which treatment should be stopped. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05025592
Study type Observational
Source Beijing Cancer Hospital
Status Not yet recruiting
Start date September 10, 2021
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT02256514 - Open Label Trial of Immunotherapy for Advanced Liver Cancer Phase 2
Not yet recruiting NCT04542837 - The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma Phase 2
Terminated NCT02785874 - Statin With Palliative Therapy for HCC N/A
Not yet recruiting NCT02715492 - Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma. Phase 3
Completed NCT02985034 - Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT N/A
Suspended NCT02935478 - Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation N/A
Completed NCT03176485 - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors N/A
Completed NCT02675920 - A Study of HCC High Risk Group Using Two Surveillance Tools
Completed NCT02833298 - Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening N/A
Recruiting NCT04588051 - Cabozantinib in Hepatocellular Carcinoma Phase 2
Not yet recruiting NCT03314532 - The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma N/A
Recruiting NCT03097848 - Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma N/A
Completed NCT03045445 - "Double Low-Dose" DECT for HCC Imaging N/A
Active, not recruiting NCT03893695 - Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) Phase 1/Phase 2
Active, not recruiting NCT01356628 - A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer Phase 2
Not yet recruiting NCT02415283 - OBT Measurement to Differentiate Between Presence and Absence of HCC Determined by MRI Phase 2
Recruiting NCT04611373 - Clinical Study on the Efficacy of Acetazolamide Combined With Levamisole in the Treatment of HCC Phase 3
Recruiting NCT03104920 - ERAS Program Improves Recovery of HCC Patient Undergoing Hepatectomy N/A
Completed NCT02645981 - Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma Phase 2/Phase 3
Recruiting NCT04843176 - Artificial Intelligence vs. LIRADS in Diagnosing HCC on CT N/A